Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
Date:2/27/2013

million during the three months and year ended December 31, 2011, respectively. The decrease is due to the introduction of generic vancomycin.

Cost of sales increased for the three months and year ended December 31, 2012 primarily due to the effect of continuing growth of Cinryze and the royalty due to Genzyme for Vancocin sales which was not payable in 2011.

Research and development costs incurred during 2012 were relatively flat compared to 2011 as the increased spending during 2012 in our various programs was offset by upfront and license payments of $15.5 million to Halozyme and a $3.0 million license payment to Intellect Neurosciences in 2011. The increase in selling, general and administrative expenses in the year ended December 31, 2012 compared to the year ended December 31, 2011 was driven by the growth of our global organization and our commercialization efforts.

We incurred other operating expenses of $8.7 million in the year ended December 31, 2012 compared to $8.5 million in the year ended December 31, 2011.  During 2012, we recognized $4.5 million of expense due to the re-measurement of the fair value of the contingent consideration and $3.7 million of start-up cost paid to suppliers. Results for 2011 included $4.7 million of expense due to the re-measurement of the fair value of the contingent consideration, $3.4 million of costs to expand Cinryze manufacturing capacity at Sanquin and an $8.5 million impairment charge related to certain assets acquired from Auralis. 

Our tax expense for the quarter was $2.5 million and $13.4 million for the year versus $10.2 million and $67.3 million for the respective prior year periods.  Our effective tax rate for 2012 was 71 percent up from 32 percent for the previous year.  The effective tax rate for 2012 was impacted by approximately 170 basis points due to the recording of a valuation allowance related to certain state net operating losses. 

Wo
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... , ROCKVILLE, Md., Dec. 9 Novavax, ... 25, 2009, it closed its previously announced public offering of ... Novavax received net proceeds from the sale of the ... approximately $21 million, which will be used for preclinical studies ...
... , GAITHERSBURG, Md, Dec. 9 Lentigen Corporation, ... of lentiviral gene delivery technologies, announced today that it ... business innovation research (SBIR) grant for a program on ... using Lentivirus". In this program, Lentigen will collaborate ...
Cached Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:9/1/2014)... Steven Reinberg ... News) -- In a head-to-head comparison, an experimental drug ... and hospitalizations in heart failure patients. According to ... of the marked benefit of the new drug, dubbed ... those getting the standard medication, enalapril (Vasotec), either died ...
(Date:9/1/2014)... An operating theatre or operating room is ... operations. An operating room comprises a myriad of specially-designed ... lights, imaging displays as well as integration systems for ... Research, a U.S.-based market research firm, the operating room ... by 2019. , According to this report, the ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Bioinformatics ... organize and analyze biological and genetic data. A ... activity of developing software tools to generate and ... be confused with biological computation. While bioinformatics simply ... of biology can its related concepts, biological computation ...
(Date:9/1/2014)... 2014 Ontraport , one of ... was developed to automate the small intricacies of managing ... Shane Michaels, prompting an investigative review. , “As ... of managing all of the small details involved with ... reports Michaels. “That’s why Ontraport has become so popular ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... , , , ... part of Mayo Clinic and Microsoft Corp.,s shared vision to help ... made enhancements to Mayo Clinic Health Manager , ... manage their health. People with conditions such as hypertension and high ...
... Germany: For the first time researchers have shown that by ... possible to make pancreatic cancer cells sensitive to chemotherapy, opening ... treat the disease. Dr Davide Melisi told Europe,s ... Berlin today (Thursday 24 September) that resistance to chemotherapy was ...
... New Series ... iPod touch. , ... (Vocus) September 24, 2009 -- Modality, Inc. and Elsevier, Inc. today announced two Procedures Consult ... help physicians, medical residents and students prepare for, perform and test their knowledge of the ...
... ... leader in automatic door sensors, BEA, Inc. is delighted our products will be welcoming ... center in the world with Gold LEED® (Leadership in Energy and Environmental Design) certification. ... Pittsburgh, Pa. ...
... ... is featured in a presentation and free downloadable slides on the Diabetes Best Practices ... Somerville, ... illnesses should focus on self-care and give them the survival skills necessary to maintain ...
... AMSTERDAM, September 24 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... Jorn Aldag as its new Chief Executive Officer, starting,October ... in the life,sciences sector and more than twenty five ... President and CEO of Evotec AG, he was,instrumental in ...
Cached Medicine News:Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 2Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 3Health News:Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 2Health News:Procedures Consult Internal Medicine Applications Now Available on App Store 3Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:New Presentation Highlights Importance of In-Hospital Hyperglycemia Management and Appropriate Discharge Planning for Diabetes Patients 2Health News:AMT Appoints New Chief Executive Officer 2Health News:AMT Appoints New Chief Executive Officer 3
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth...
Medicine Products: